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ABSTRACT 
 
RNA interference (RNAi) is mediated by a multicomponent RNA-induced silencing complex (RISC). Here 
we examine the phosphorylation state of three Drosophila RISC-associated proteins, VIG, R2D2 and a trun-
cated form of Argonaute2 devoid of the nonconserved N-terminal glutamine-rich domain. We show that of 
the three studied proteins, only VIG is phosphorylated in cultured Drosophila cells. We also demonstrate that 
the phosphorylation state of VIG remains unchanged after cell transfection with exogenous dsRNA. A se-
quence similarity search revealed that VIG shares significant similarity with the human phosphoprotein Ki-
1/57, a known in vivo substrate for protein kinase C (PKC). In vitro kinase assays followed by tryptic phos-
phopeptide mapping showed that PKC could efficiently phosphorylate VIG on multiple sites, suggesting 
PKC as a candidate kinase for VIG phosphorylation in vivo. Taken together, our results identify the RISC 
component VIG as a novel kinase substrate in cultured Drosophila cells and suggest a possible involvement 
of PKC in its phosphorylation. 
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INTRODUCTION 
 
In Drosophila, one of the most versatile and thoroughly 
studied model organisms, several proteins have been im-
plicated in RNAi induced by exogenous dsRNA. Dicer 2 
(DCR-2), an RNAse III family nuclease, cleaves the intro-
duced long dsRNA into multiple short interfering RNAs 
(siRNAs)  instructing  a  multicomponent  RNA-induced 
silencing  complex  (RISC)  to  destroy  homologous  target 
mRNAs (Zamore et al, 2000; Bernstein et al, 2001; Lee et 
al, 2004). A protein named R2D2 stably associates with 
DCR-2  (Liu  et  al,  2003)  and  functions  as  a  sensor  for 
siRNA asymmetry (Tomari et al, 2004). The core RISC 
protein Argonaute2 (Ago2) (Hammond et al, 2001) is the 
catalytic engine behind target mRNA cleavage (Liu et al, 
2004; Song et al., 2004). Other RISC components include 
Tudor-SN  (TSN)  (Caudy  et  al,  2003),  dFMR1  (alterna-
tively  named  dFXR;  Caudy  et  al,  2002;  Ishizuka  et  al, 
2002) and a protein named VIG, encoded from within an 
intron of the Vasa gene (Caudy et al, 2002). Four more 
proteins,  Armitage,  Spindle  E,  Rm62,  and  Dmp68  are 
thought to be involved in the assembly of RISC (reviewed 
by Meister and Tuschl, 2004; Sontheimer, 2005).  
 
Reversible protein phosphorylation is a central mechanism 
controlling  protein function  in living cells.  At least  one 
protein  component  of  the  Drosophila  RISC,  dFMR1,  is 
phosphorylated in vitro and  in vivo (Siomi et al, 2002). 
Protein kinase CK2 (formerly known as casein kinase 2) 
has  been  implicated  in  the  phosphorylation  of  dFMR1. 
The  phosphorylation  site  has  been  mapped  to  Ser406, 
which is highly conserved among FMR family members 
from  several  species.  Human  and  murine  orthologs  of 
dFMR1  are  primarily  phosphorylated  on  the  same  con- 
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served serine residue within the CK2 consensus sequence 
(Siomi et al, 2002; Ceman et al, 2003). Phosphorylation at 
this site regulates dFMR1 oligomerization and RNA bind-
ing, suggesting that the biological functions of dFMR are 
regulated  by  phoshorylation  (Siomi  et  al,  2002).  Phos-
phorylation analysis of other proteins involved in RNAi 
has not been reported. The aim of this study was to exam-
ine the phosphorylation status of VIG, R2D2 and Ago2 in 
cultured Drosophila cells. 
 
MATERIALS AND METHODS 
 
Construction  of  expression  plasmids  and  stable 
transfection 
The cDNA clones RE04347 (Ago2, CG7439), LD07162 
(VIG, CG4170) and AT28705 (R2D2, CG7138) were ob-
tained from the MRC Geneservice, Cambridge, UK. The 
coding  sequences  of  VIG,  R2D2  and  Ago2  were  PCR-
amplified from the corresponding cDNA clones using the 
primers shown in Table 1. The PCR products were topoi-
somerase-cloned into pMT/V5-His-TOPO expression vec-
tor  (Invitrogen,  Carlsbad,  CA)  containing  the  metal-
inducible  metallothionein  promoter  and  the  C-terminal 
V5-polyhistidine (His) tag. Stable cell lines were gener-
ated according to the Drosophila Expression System pro-
tocol  (Invitrogen).  Recombinant  protein  expression  was 
assayed by western blotting with anti-V5 antibodies. 
 
 
Table 1. Oligonucleotide primers used in the present study 
 
Purpose  Polarity  Sequence 5’ ￿ ￿ ￿ ￿ 3’ 
sense  ACC ATG GAT AAC AAG TCA GCC 
GTA TCT GCT  R2D2 
amplification 
  antisense 
AAT CAA CAT GGT GCG AAA ATA 
GTC TAT 
sense  ACC ATG GAC AGC GCC GGT AAA 
AAT CGT TAT  VIG 
amplification 
  antisense  AGC CAG AGT GGG AAA CTG ACG 
CTC ATC 
sense 
ACC ATG GCA CCT TCT GTG GCA 
TAC CAC TAT  Ago2a 
amplification 
  antisense 
GAC AAA GTA CAT GGG GTT TTT 
CTT CAT 
sense  TAA TAC GAC TCA CTA TAG GGA 
TCG AGC GGC AAA TGG ATG CTG  Actn  dsRNA 
preparation 
  antisense 
TAA TAC GAC TCA CTA TAG GGC 
TTG TCG GCT GCC AGG ATT CGG 
 
Note: The sequence corresponding to the T7 RNA polymerase binding 
site is underlined. 
 
 
Enzymatic preparation of dsRNA 
A 585 nt-long fragment of the largest exon of the α-actinin 
gene  was  PCR-amplified  from  a  Drosophila  cDNA  li-
brary. Each of the PCR primers incorporated a 5’ T7 RNA 
polymerase minimum binding site (see Table 1 for primer 
sequences). In vitro transcription, annealing and purifica-
tion  of  dsRNA  were  carried  out  using  a  MEGAscript 
RNAi kit according to the manufacturer’s protocol (Am-
bion, Austin, TX). 
 
RNAi experiments 
S2  cells  were  resuspended  at  a  final  concentration  10
6 
cells/ml in serum free Schneider’s medium. Viability was 
examined by trypan blue dye exclusion. dsRNA was added 
to the medium at a concentration of 15-30 µg per 10
6 cells. 
Cells were mixed with dsRNA by gentle swirling and in-
cubated  for  1  hr  at  room  temperature.  Subsequently, 
Schneider’s  medium  supplemented  with  10%  (v/v)  fetal 
calf serum was added and the cells were incubated for an 
additional 5 days to allow for turnover of the target pro-
tein. The efficiency  of silencing was determined by im-
munoblotting of cell lysates with a specific antibody. 
 
Metal  affinity  precipitation  and  selective  phospho-
protein staining 
5-10  x  10
6  stably  transfected  cells,  treated  or  untreated 
with α-actinin dsRNA, were incubated for 18 hr in com-
plete  Schneider’s  medium  containing  500  µM  CuSO4. 
Cells were collected by centrifugation, rinsed with PBS, 
and immediately lysed in 4 ml of buffer A (6 M guanidine 
hydrochloride, 100 mM NaH2PO4, 10 mM Tris-HCl, pH 
8.0). The lysates were cleared by centrifugation at 16000 x 
g for 10 min and incubated on a shaker for 30 min with 
100 µl of Ni-NTA agarose (50% slurry pre-equilibrated in 
buffer A; Qiagen, Valencia, CA). The resin was collected 
by centrifugation at 400 x g for 5 min and washed with 10 
ml  of buffer A. Supernatant was carefully removed and 
washing was repeated with buffer B (8 M urea, 100 mM 
NaH2PO4, 10 mM Tris-HCl, pH 8.0), then with buffer C 
(same composition as buffer B, pH 6.0). His-tagged pro-
teins were eluted with 100 µl of buffer E (same composi-
tion  as  buffer  B, pH  4.5)  and  subjected  to  SDS-PAGE. 
Gels  were  stained  with  ProQ-Diamond  phosphoprotein 
stain (Molecular Probes, Eugene, OR) and SYPRO Ruby 
total  protein  stain  (Molecular  Probes)  according  to  the 
manufacturer’s protocol. Gel images were acquired with a 
Fuji FLA-5100 system using a 532 nm laser and a 575 nm 
long pass filter (Fujifilm, Tokyo, Japan). 
 
Metabolic  [
32P]-orthophosphate  labelling  and  immuno-
precipatation 
5-10 x 10
6 stably transfected S2 cells were rinsed once and 
incubated  overnight  in  phosphate/yeastolate-depleted 
Schneider’s medium (Specialty  Media, Phillipsburg,  NJ) 
containing  250  µCi/ml  [
32P]-orthophosphate  (HCl-free; 
Amersham Pharmacia Biotech, Uppsala, Sweden) and 500 
µM CuSO4. Prior to labeling, cells were either treated or 
untreated with α-actinin dsRNA. Labeled cells were col-
lected by centrifugation (250 x g, 10 min), solubilized in 
NET buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 5 
mM EDTA, 25 mM NaF, 1 mM Na3VO4, 0.5% Nonidet P-
40)  containing  1%  SDS  and  immediately  boiled  for  15 
min. The lysates were transferred to fresh tubes and di-
luted (1:10) with NET buffer supplemented with 2% (w/v) 
BSA and Complete EDTA-free protease inhibitor cocktail 
(Roche,  Basel,  Switzerland).  Presoaked  protein  A-
Sepharose (Amersham Pharmacia Biotech) was added at 
1% (w/v) to the diluted lysate and incubated on a rotator 
for 1.5 hr at 6
oC to remove Sepharose-binding proteins. 
Following  centrifugation  1500  x  g  for  10  min,  rabbit 
polyclonal anti-V5 antibody (Sigma, St. Louis, MO) pre-
bound to protein A-Sepharose was added to the super-
natant and incubated on a rotator overnight at 6
oC. The 
immunoprecipitate  was  collected  by  centrifugation  at 
1000 x g for 10 min, washed four times with NET buffer, 
and  analyzed  by  western  blotting  with  mouse  anti-V5 
IgG (Invitrogen). The membrane was exposed to an im- 
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age plate for 48 hr and then scanned using a phosphor 
imager (Fujifilm).  
 
In vitro phosphorylation assays 
VIG-expressing  cells  were  immunoprecipitated  with 
rabbit anti-V5 antibody as described above. Precipitated 
immunocomplexes were washed with kinase buffer (20 
mM HEPES, pH 7.4, 1.7 mM CaCl2, 5 mM MgCl2, 1 
mM dithiothreitol) and incubated for 25 min at 30
oC in 
the same buffer containing 0.6 mg/ml phosphatidylser-
ine, 2 µM ATP, 1 µCi [γ-
32P]ATP and 25 ng of purified 
rat brain PKC (a mixture of predominantly α, β and γ 
isoforms; Promega, Madison, WI). The reactions were 
supplemented with 2 mM MnCl2 and further incubated 
for 15 min at 30
oC in the absense or presence of 7 U/µl 
recombinant lambda protein phosphatase (New England 
Biolabs,  Beverly,  MA).  The  immunoprecipitates  were 
washed  three  more  times with  NET  buffer to  remove 
unincorporated  [γ-
32P]ATP  and  analyzed  by  western 
blotting and autoradiography as described in the previ-
ous paragraph. 
 
Enzymatic dephosphorylation assays 
Metal  affinity-precipitated  proteins  were  microdialyzed 
against milli-Q water to remove urea and other salts. Dialyzed 
proteins  were  incubated  for  30  min  at  30
oC  in  a  reaction 
buffer (50 mM Tris-HCl, pH 7.5, 0.1 mM Na2EDTA, 5 mM 
dithiothreitol,  0.01%  Brij  35)  supplemented  with  2  mM 
MnCl2  in  the  presence  or  absence  of  7  u/µl  recombinant 
lambda protein phosphatase (New England Biolabs). Samples 
were resolved by SDS-PAGE and gels were stained with Pro-
Q Diamond and SYPRO Ruby. Alternatively, gels were im-
munoblotted with anti-V5 antibodies. 
 
Two-dimensional tryptic phosphopeptide mapping 
Tryptic  phosphopeptide  mapping  was  carried  out as  de-
scribed previously (Ivanov et al, 2003). 
 
RESULTS 
 
Analysis of VIG, R2D2 and Ago2 expression in stable 
cell lines 
Drosophila Schneider 2 (S2) cells have proven to be a 
powerful tool for analysis of protein function and dissec-
tion of biochemical pathways. In this study, we generated 
stable S2 cell lines to examine the phosphorylation status 
of VIG, R2D2 and Ago2. Western blotting with anti-V5 
antibodies confirmed that the cell lines expressed R2D2 
and VIG (Figure 1, left panel). The size of each protein 
corresponded  to  the  predicted  molecular  weight  of  the 
fusion protein containing the V5 and His epitope tags. 
No protein reactive with anti-V5 antibodies was detected 
in lysates of nontransfected  cells (Figure 1, lanes WT).  
 
Both R2D2 and VIG were expressed at levels high enough 
to allow metal affinity purification and subsequent phos-
phorylation  analysis.  However,  cells  stably  transfected 
with a plasmid carrying the complete open reading frame 
of the Ago2 gene showed very low expression, often be-
low the detection limit of western blotting. To overcome 
this problem, we followed the approach of Hammond et al 
(2001) and deleted the N-terminal domain of Ago2 com-
posed of glutamine-rich repeats. The deletion resulted in a 
shorter protein that initiates from the second methionine 
codon of the open reading frame, retaining the functionally 
important  PAZ  and  PIWI  domains  (Cerutti  et  al,  2000; 
Carmell et al, 2002). The stable cell line expressing the 
truncated  form  of  Ago2  (designated  further  as  Ago2a) 
produced significantly more recombinant protein (Figure 
1,  right  panel)  than  the  one  expressing  the  full-length 
Ago2. 
 
   
 
 
 
Figure 1. Expression of recombinant R2D2, VIG and Ago2a in 
cultured S2 cells. Stable cell lines were either treated (+) or un-
treated (-) with CuSO4 to modulate expression of the C-terminal 
V5-His fusion proteins. Shown are immunoblots of total cell 
lysates probed with anti-V5 antibodies. The first lane in each blot 
contained the lysate of wild type (WT) S2 cells. Molecular mass 
standards (in kilodaltons) are shown at left on each blot. 
 
 
VIG, but not R2D2 or Ago2a, is phosphorylated in vivo 
Since R2D2 and VIG fusion proteins were expressed in 
stable cell lines at relatively high levels, we examined their 
in vivo phosphorylation status by selective phosphoprotein 
staining. The proteins were isolated by metal affinity pre-
cipitation, resolved by gel electrophoresis and stained with 
Pro-Q Diamond fluorescent stain (Figure 2A, left panel) 
that selectively  detects  phosphoproteins (Steinberg et al, 
2003). Although the most intense bands in the Pro-Q Dia-
mond-stained gels usually correspond to phosphoproteins, 
nonspecific background staining may  also  be  observed 
with high levels of sample. To distinguish between a low-
abundance  phosphoprotein  and  a  high-abundance  non 
phosphorylated protein, we stained the same gels for total 
protein  with a quantitative  SYPRO Ruby stain (Figure 
2A, right panel). The relative intensities of total protein 
bands were compared with those  observed in the Pro-Q 
Diamond-stained gels. Comparison of the staining patterns 
revealed  that  VIG  was  specifically  stained  with  Pro-Q 
Diamond, suggesting that it  is a phosphoprotein (Figure 
2A,  lane  4).  In  contrast,  only  background  staining  was 
observed for R2D2 (Figure 2A, lane 2). 
 
Because the expression levels of Ago2a were lower than 
those obtained for R2D2 and VIG, we employed two inde-
pendent experimental approaches to test whether Ago2a is 
a phosphoprotein. The first approach, based on gel staining 
with  Pro-Q  Diamond,  showed  no  phosphorylation  of 
Ago2a (Figure 2B, lane 2).  To verify this result, we took a  
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Figure 2. Phosphorylation status of R2D2, VIG and Ago2a in cultured S2 cells. Stable cell lines were incubated in the absence (-) or 
presence (+) of Actn dsRNA, and expression of R2D2, VIG (A) or Ago2a (B) was induced with CuSO4. The proteins were isolated by 
metal affinity precipitation, resolved by SDS-PAGE, and gels were stained with ProQ-Diamond and SYPRO Ruby. The first lane in each 
gel contained molecular mass marker proteins including one phosphoprotein (ovalbumin) that served as a positive control for ProQ-
Diamond staining (marked with an asterisk). (C) Stable cell line expressing Ago2a was incubated in the absence (-) or presence (+) of 
Actn dsRNA and metabolically labeled with [
32P]-orthophosphate. The immunoprecipitated Ago2a was analyzed by western blotting 
with anti-V5 IgG (left panel) and the membrane was subjected to autoradiography (right panel). The sizes of marker proteins are indi-
cated in kilodaltons, and the positions of R2D2, VIG and Ago2a are marked with arrowheads. Material precipitated from wild type (WT) 
S2 cells was used as a negative control. 
 
 
second  approach  based  on  radioactive  labeling  and  im-
munoprecipitation.  Stably  transfected  cells  expressing 
Ago2a  were  metabolically  labeled  with  [
32P]  orthophos-
phate and the protein was immunoprecipitated with anti-V5 
antibody. In agreement with the result obtained with Pro-Q 
Diamond staining, the immunoprecipitated Ago2a did not 
detectably incorporate [
32P] orthophosphate (Figure 2C, lane 
2).  Thus,  we  concluded  that  among  the  studied  proteins, 
VIG was the only protein phosphorylated in S2 cells. 
 
To further verify that VIG is a phosphoprotein, we per-
formed  in  vitro  dephosphorylation  assays  with  lambda 
protein  phosphatase  (λ-PPase).  VIG  was  isolated  from 
induced cells by metal affinity precipitation, treated with 
λ-PPase and subjected to gel electrophoresis followed by 
Pro-Q Diamond  staining.  The  staining  was  substantially 
reduced by phosphatase treatment (Figure 3) unequivocally 
confirming that VIG was modified by phosphorylation. 
 
The phosphorylation status of VIG, R2D2 and Ago2a 
remains unchanged after cell treatment with dsRNA 
S2 cells can take up long dsRNA directly from the culture 
medium  (Clemens  et  al,  2000).  This  makes  these  cells 
ideal for studying protein phosphorylation events induced 
by  exogenous  dsRNA.  When  introduced  into  the  cells, 
dsRNA  facilitates  sequence-specific  degradation  of  cog-
nate mRNA through RNAi, leading to selective depletion 
of the encoded protein. In this study, we incubated cells 
with dsRNA corresponding to a fragment of the Droso-
phila  α-actinin  (Actn)  gene  encoding  an  actin  filament-
binding  protein  (Otey  and  Carpen,  2004).  After  dsRNA 
treatment,  cultures  were  grown  for  five  more  days,  the 
maximum  time  normally  allowed  for  protein  depletion. 
During all this time the cells were viable and maintained 
normal morphology. The RNAi efficiency was estimated 
by comparing α-actinin levels in dsRNA-treated and un-
treated cells. Immunoblotting of cell lysates with anti-Actn 
antibody showed significant depletion of α-actinin (Figure 
4),  confirming  that  Actn  dsRNA  has  been  successfully 
delivered into the cells. 
 
To  test  whether  cell  treatment  with  dsRNA  affects  the 
phosphorylation status of R2D2, VIG or Ago2a, we iso-
lated the proteins from stable cell lines incubated with or 
without Actn dsRNA. The intake of dsRNA by S2 cells is 
a relatively fast process,  resulting  in  degradation of cog-  
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Figure 3. VIG dephosphorylation with λ-PPase. The protein was 
isolated from the VIG-expressing cell line, treated (+) or un-
treated (-) with λ-PPase, resolved by SDS-PAGE and subjected 
to specific phosphoprotein staining. Ovalbumin was used as a 
positive staining control (marked with an asterisk). The size of 
molecular mass standards (in kilodaltons) is indicated at left. The 
loading controls are shown in lower panels. 
 
 
 
 
 
Figure 4. Preparation of Actn dsRNA and specific protein deple-
tion. The upper panel shows a PCR fragment of ~600 nt corre-
sponding to the largest exon of the α-actinin gene flanked by T7 
RNA polymerase minimum binding sites. The PCR fragment 
was used as a template for in vitro transcription to synthesize the 
corresponding dsRNA. Five days after cell treatment with Actn 
dsRNA, total cell lysates were subjected to immunoblotting with 
anti-α-actinin antibody. Gel staining with Coomassie was used as 
a loading control. The sizes of marker proteins are indicated in 
kilodaltons. 
 
 
nate mRNA within 24 hr (Dubrovsky et al, 2004). Subse-
quent protein depletion usually takes 1-5 days, depending 
on  the  protein  turnover  rate.  Therefore,  cell  incubations 
with Actn dsRNA were carried out for 18 hr, enough to 
introduce dsRNA into the cells, but not enough to signifi-
cantly  deplete  α-actinin.  This  helped  minimize  possible 
adverse  effects  of  α-actinin  depletion  on  target  protein 
phosphorylation.  Staining  with  Pro-Q  Diamond  and 
SYPRO Ruby revealed that the phosphorylation state of 
VIG, R2D2 and Ago2a remained unchanged following cell 
incubation  with  dsRNA.  Similar  phosphorylation  levels 
were observed for VIG (Figure 2A, lane 5), while neither 
R2D2 nor Ago2a became phosphorylated (Figures 2A and 
2B,  lanes 3).  The  absence  of  Ago2a phosphorylation  in 
dsRNA-treated  cells  was  also  confirmed  by  radioactive 
orthophosphate labeling (Figure 2C, lane 3). Thus, treat-
ment of S2 cells with dsRNA had no immediate effect on 
VIG  phosphorylation  and  was  unable  to  activate  phos-
phorylation of R2D2 or Ago2a. 
 
VIG is efficiently phosphorylated by purified protein 
kinase C on multiple sites 
The present finding that VIG is a phosphoprotein prompted 
us to perform a homology search in an attempt to find simi-
lar  phosphoprotein(s) in other  organisms.  The  search  re-
vealed that VIG shares significant sequence similarity with 
a human phosphoprotein Ki-1/57 (Figure 5). 
 
Ki-1/57 (alternatively named HABP4) belongs to an evolu-
tionarily  conserved  protein  family  present  in  organisms 
ranging from yeast to mammals. It has been long known 
that Ki-1/57 coimmunoprecipitates with a serine/threonine 
protein kinase activity (Hansen et al, 1990). On this basis, it 
was originally suggested that Ki-1/57 is a protein kinase, 
but cloning of its cDNA revealed the absence of any kinase 
domains  in  the  protein  sequence  (Kobarg  et  al,  1997; 
Huang et al, 2000). Recently, the kinase activity associated 
with Ki-1/57 has been attributed to protein kinase C (PKC), 
and  the  PKC-mediated  phosphorylation  of  Ki-1/57  has 
been demonstrated in vitro and in vivo (Nery et al, 2004). 
Therefore, we next sought to determine whether VIG could 
also  be  phosphorylated  by  PKC.  To  this  end,  lysates  of 
VIG-expressing cells were immunoprecipitated with anti-
V5 antibodies and subjected to in vitro kinase assays with 
purified rat brain PKC. Figure 6A, lane 2 shows that im-
munoprecipitated  VIG  was  readily  phosphorylated  by 
PKC. As expected, VIG phosphorylation was reversed by 
phosphatase treatment (Figure 6A, lane 1), and no phos-
phorylated band corresponding to VIG was detected in 
immunocomplexes obtained from wild type cells (Figure 
6A,  lane  WT).  As  a  next  step,  we  analyzed  PKC-
mediated  phosphorylation  of  VIG  by  two-dimensional 
tryptic phosphopeptide mapping. We observed more than 
ten  radioactive  spots  on  a  tryptic  peptide  map  (Figure 
6B),  indicating  that  VIG  is  phosphorylated by  PKC  in 
vitro on multiple sites. 
 
DISCUSSION 
 
The major finding of the present study is that VIG, a com-
ponent of the RNA-induced silencing complex, is phos-
phorylated in vivo. To our knowledge, this is the first re-
port  showing  that  the  Vasa  intronic  gene  product  is  a 
phosphoprotein. Of the three proteins tested, only VIG was 
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Dm     1 -------------------MDSAGKNRYELLFMDDDVSDPLDNLVAPTAAAAAAAAGKKK 
Hs_K   1 MKGALGSPVAAAGAAMQESFGCVVANRFHQLLDDE--SDPFDILREAERRRQQQLQRKRR 
Hs_P   1 MPGHL-----------QEGFGCVVTNRFDQLFDDE--SDPFEVLKAAENKKKEAGGGG-- 
Gg     1 MPGHL-----------QEGFGCVVTNRFDQLFDDE--SDPFEVLRAAESRRKESGGGGGG 
Dr     1 MPGHL-----------QEGFGCVVTNRFDQLFDDE--EDPFEVLKQAEKKKKDATVPG-- 
Xt     1 MPGHL-----------QEGFGCVVTNRFDQLFDDE--SDPFEVLKAAENKKKEGAGGP-- 
 
 
Dm    42 QPSAAAAAATKTTANKVANSNNKANAG--------SNIGGPNAKKPNQAEKENKPNNALN 
Hs_K  59 DEAAAAAGAGPRGGRSPAGASG--------------HRAGAGGRRESQKERKSLPAP--- 
Hs_P  46 VGGPGAKSAAQAAAQTNSN------------------AAGKQLRKESQKDRKNPLPPSVG 
Gg    48 AQGGGGARGGPAGAQSNSSGGAGGGGPGQAGSGGGAGSAAKQLRRESQKERKNPLPPFAA 
Dr    46 --------AAKTAAQ-----------------------AAKQPKKESQKERRNPLPD--- 
Xt    46 -----GQGTGKTAAQ-----------------------AAKQPKKESQKDRKNPLS---- 
 
 
Dm    94 KTDGKKFTPSADNKQQQFNNNASSNYKQQGAPRQGGGANRTREFG--------------- 
Hs_K 102 --------------VAHRPDSPGGGLQAPGQKRTPRRGEQQGWN---------------- 
Hs_P  88 VVD----------KKEE--TQPPVALKKEGIRRVGRRPDQQLQ----------------- 
Gg   108 SAGGE--------RREEGGGQPGAPLRKEGIRRIGRRPDQQQQQ---------------- 
Dr    72 -------------KKEE--TQAPVPLKKDGMRKMGRRPEQQGQQ---------GSQQQQQ 
Xt    74 -------------EKEEK-SQAPVPIKKEAIRRVGRRPDQQQQPPQQPPTQQQQQQQQQQ 
 
 
Dm   139 --------SGQGQGQGQGGQQQRSVNFRQQNGNAETREQRNNRRNVRENVGAPDGQQSRP 
Hs_K 132 ----------DSRGPEGMLERAERRSYREYRPYETERQADFTAEKFPDEKPGDRFDRDRP 
Hs_P 119 -----------GEGKIIDRR-PERRPPRERRFEKPLEEK-GEGGEFSVDRP----IIDRP 
Gg   144 ---------QQGEGKPIDRR-PERRPPRERRFDKPADEK-GEGGEFSVDKP----ILDRP 
Dr   108 QQQVPQQQAGQGEGRPPADRRPDRRPPRERRFDKPADEKPAEGGEFSVEKT----MGDRP 
Xt   120 QQQQQPPQSSQGEGKPVDRRQSDRRPPRERRFEKPTEEK-GEAGEFSVDRP----IVDRP 
 
 
Dm   191 YRGPGGGPG----AGGDRPQRQNRNYDGQNRKREFDRQSGSDR-----TGVKSIDKRDGA 
Hs_K 182 LRGRGGPRGGMRGRGRGGPGNRVFDAFDQRGKREFERYGGNDK-----IAVRTEDNMGGC 
Hs_P 162 IRGRGGLGR---GRGGRGRGMGRGDGFDSRGKREFDRHSGSDR-----SGLKHEDKRGGS 
Gg   189 MRGRGGLGR---GRG-RGRGMGRGDGFDSRGKREFDRHSGSDR-----SGLKHEDKRGGS 
Dr   164 FRGRGGPRG---GRGGRGRGVGRTDGFDSRGKREFDRHSGSDR------SLKAEEKRGGS 
Xt   175 IRGRGGPGGRG-GRGGRGRGLGRGDGFDSRGKREFDRHSGSDRASSHFSGPKHEDKRGGS 
 
               *PKC                           *                  *    
Dm   242 GSHNWGSVKEAIDDVNKNESETNVTNAEGG--AKADESGTEPQNEQATAEEEAKELTLDE 
Hs_K 237 GVRTWGSGKDT-SDVEPTAPMEEPTVVEESQGTPEEESPAKVPELEVEEETQVQEMTLDE 
Hs_P 214 GSHNWGTVKDELTDLDQSNVTEETPEGEEH--HPVADTENKENEVEEVKEEGPKEMTLDE 
Gg   240 GSHNWGTVKDELTELDQSAVTEETPEGEE---HPPADSENKENEVEEVKEEGPKEMTLDE 
Dr   215 GSHNWGTVKDELSELDQSNVTEDTPEGEE---HPPADSENKENEVEEAKEEGPKEMSLDE 
Xt   234 GSHNWGTVKDELSELDQSAVTEETPETEE---HPAVDSENKENEAEEVKEEGPKEMTLDE 
 
 
Dm   300 WKAQQGQ-RIKPTFNIRKAGEGEDTTQWKKMVVLTSNKKKENDSEEELEYDPALYPQRVG 
Hs_K 296 WKNLQEQTRPKPEFNIRKPESTVP----SKAVVIHKSKYRDDMVKDDYEDD--SHVFRKP 
Hs_P 272 WKAIQNKDRAKVEFNIRKPNEGADG-QWKKGFVLHKSKSEEAHAEDSVMD----HHFRKP 
Gg   297 WKAIQSKDRAKVEFNIRKPNEGADG-QWKKGFVLHKSKSEEAHAEDSVMD----HHFRKP 
Dr   272 WKAQQDKERAKVEFNIRKANEGAD---WKKGYVLHKSKAEDASADDAAGD----HHFRKP 
Xt   291 WKAMQDKERSKVEFNIRKPNEGADG-QWKKGFVLHKAKSDEVHAESDALD----HHFRKP 
 
 
Dm   359 RQQRVLDIQFNFNDGRRGGPGGFGGRGGRGGPRPGGFGGGPRSEGGNRDGGNREGGRDNR 
Hs_K 350 ANDITSQLEINFGNLPRPGRGAR--GGTRGGRGRIR------------------------ 
Hs_P 327 ANDITSQLEINFGDLGRPGRGG---RGGRGGRGRGG------------------------ 
Gg   352 ANDITSQLEINFGDLGRPGRGG---RGGRGGRGRGG------------------------ 
Dr   325 ANDITSQLEINFGDLGRPGRGRGGPRGGRGGRGAAAA----------------------- 
Xt   346 ANDITSQLEINFGDLGRPGRGG---RGGRGGRARGG------------------------ 
 
 
Dm   419 EGGNRGPRDGQQHNNEGGGSSAQNQRPPIDRRGPGNNQNNNQNSGPGPNKRFERQQNTAP 
Hs_K 384 -------------------------------RAENNYPRAEV-----------VMQDVAP 
Hs_P 360 -------------------------------RPNRGSRTDK-------------SSASAP 
Gg   385 -------------------------------RASRGGRTDKLVKEFDVIHTPNQSSASAP 
Dr   362 ------------------------------TRPPRERRPDK------------VGGVSVP 
Xt   379 -------------------------------RPSRGGRTDK-------------SNASAP 
 
 
Dm   479 KVNDERQFPTLA 490 
Hs_K 402 NPDDPEDFPALS 413 
Hs_P 376 DVDDPEAFPALA 387 
Gg   414 DVDDPEAFPALS 425 
Dr   380 NVDDPEAFPALA 391 
Xt   395 DVDDPEAFPALA 406 
 
 
 
Figure 5. Multiple sequence alignment of the Drosophila VIG with its vertebrate homologs. Abbreviations: Dm, Drosophila 
melanogaster; Hs_K, Homo sapiens Ki-1/57; Hs_P, Homo sapiens PAI-RBP1; Gg, Gallus gallus; Dr, Danio rerio; Xt, Xenopus 
tropicalis. The alignment was produced with the ClustalW server at the European Bioinformatics Institute 
(http://www.ebi.ac.uk/clustalw). Amino acid identity and similarity are indicated in black and grey shading, respectively. Asterisks 
indicate fully conserved putative phosphorylation sites predicted by the NetPhos 2 0 server 
(http://www.cbs.dtu.dk/services/NetPhos).  
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Figure 6. In vitro phosphorylation of VIG by PKC. (A) Im-
munoprecipitated VIG was assayed for phosphorylation by puri-
fied rat brain PKC in the presence of [γ-
32P]ATP. The reaction 
mixtures were treated (lane1) or not (lane 2) with λ-PPase. Mate-
rial precipitated from wild type (WT) S2 cells was used as a 
negative control. Proteins were separated by 12% (w/v) SDS-
PAGE and immunoblotted with anti-V5 antibody, and phos-
phorylation was detected by autoradigraphy. (B) The radio-
labeled, phosphorylated VIG was transferred to a membrane, 
digested with trypsin and released peptides were separated by 
thin layer electrophoresis in the first dimension and chromatog-
raphy in the second. Shown is the autoradiogram of the dried 
cellulose plate. 
 
 
phosphorylated in S2 cells. The presence of identical V5-
His tags in all three proteins ruled out that VIG could be 
artificially  phosphorylated  within  the  tag  sequence.  Be-
cause we were unable to obtain sufficient amounts of the 
full-length Ago2, we examined the phosphorylation status 
of its truncated form Ago2a. The protein retained the con-
served and functionally important PAZ and PIWI domains, 
but  lacked  the  N-terminal  glutamine-rich  domain.  This 
domain, composed largely of glutamine residues, also has 
a number of serines, threonines, tyrosines and histidines 
that may potentially become phosphorylated. Phosphoryla-
tion of these residues, however, is unlikely to be important 
for Ago2’s role in RNAi, since the glutamine-rich domain 
is not well conserved among the Argonaute family mem-
bers. Nonetheless, a degree of caution should be exercised 
when extrapolating the results obtained for Ago2a to the 
full-length protein.  
 
In this work, we demonstrate that VIG can be efficiently 
phosphorylated  by  mammalian  PKC  in  vitro.  A  similar 
kinase is responsible for the in vivo phosphorylation of the 
VIG homolog Ki-1/57 (Nery et al, 2004). Therefore, mem-
bers of the Drosophila PKC family (Shieh et al, 2002) may 
be suggested as candidate kinases for VIG phosphorylation 
in S2 cells. We observed no change in the phosphorylation 
state of VIG after cell treatment with dsRNA. This result is 
consistent with the possible involvement of PKC, a dsRNA-
independent  kinase,  in  the  phosphorylation  of  VIG.  A 
search  with  NetPhos  2.0  (Blom  et  al,  1999)  revealed  17 
potential phosphorylation sites in VIG, three of which are 
fully  conserved  between  VIG,  Ki-1/57  and  other  similar 
vertebrate proteins (Figure 5). Analysis of the VIG sequence 
with  ScanProsite  (Swiss  Institute  of  Bioinformatics; 
http://www.expasy.ch/tools/scanprosite) showed that it con-
tains at least three putative PKC phosphorylation motifs, 
and one of them is fully conserved in vertebrates. The 
presence  of  several  PKC  phosphorylation  sites  in  VIG 
was  confirmed  by  tryptic  phosphopeptide  mapping  of 
VIG  phosphorylated  by  PKC  in  vitro.  However,  it  re-
mains  to  be determined  whether  these sites  are indeed 
phosphorylated in vivo. 
 
Several lines  of evidence  indicate that VIG  is a  protein 
component  of  the  RNAi  pathway.  VIG  associates  with 
RISC, binds the RISC nuclease Ago2 and co-precipitates 
with siRNAs (Caudy et al, 2002; Pham et al, 2004). The 
protein is required for efficient RNAi in S2 cells, as dem-
onstrated  by  the  50%  decrease  in  silencing  efficiency 
caused by VIG suppression (Caudy et al, 2002). However, 
the exact function of VIG remains unclear. In this study, 
we found that VIG is similar to the human phosphoprotein 
Ki-1/57. Based on the functions of interacting partners and 
the protein localization, Ki-1/57 and another member of 
the VIG protein family, PAI-RBP1 (Heaton et al, 2001), 
have been proposed to be involved in chromatin remodel-
ing and transcriptional regulation (Nery et al, 2004). Inter-
estingly,  both  of  these  processes  are  implicated in  tran-
scriptional  gene  silencing  (TGS).  TGS  is  a  form  of 
dsRNA-induced silencing that leads to targeted chromatin 
modification and transcriptional shutdown (Almeida and 
Allshire,  2005).  It  serves  as  a  natural  defense  against 
transposons and participates in cellular programs of gene 
expression and development. Both RNAi and TGS path-
ways recruit RISC effector complexes and share common 
components such as Dicer and Argonaute. Despite rapid 
progress  in  understanding  the  molecular  mechanism  of 
TGS, many questions remain about the identities and func-
tions of the pathway components responsible for chroma-
tin  silencing  in  metazoans.  The  similarity  between  the 
known RISC component VIG and Ki-1/57, a protein with 
a suggested role in chromatin remodeling and transcrip-
tional regulation, raises an intriguing possibility that VIG 
may be involved in TGS.  
 
Reversible  phosphorylation  is  arguably  one  of  the  most 
important means of regulating protein function. Therefore, 
it  is  tempting  to  speculate  that  VIG  function  in  RISC 
might  be  regulated  by  phosphorylation.  To  address  this  
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possibility, it would be necessary to have a better under-
standing of the molecular details of VIG phosphorylation. 
Further work is required to map the phosphorylation sites 
in VIG and determine which of them are functionally sig-
nificant. The identity of the protein kinase(s) involved in 
VIG  phosphorylation  also  remains  to  be  established. 
Analysis of VIG phosphorylation in cells treated with PKC 
activators, inhibitors or PKC dsRNA may help determine 
whether VIG is a true substrate for PKC in vivo. Thus, the 
present study provides a starting point for future research 
on VIG phosphorylation and its possible role in RNAi and 
related processes. 
 
CONCLUSIONS 
 
• VIG, a component of the RNA-induced silencing com-
plex, is a target for phosphorylation in vivo. 
 
• Cell treatment with exogenous dsRNA has no effect on 
the phosphorylation state of VIG, indicating that dsRNA-
independent kinase(s) are responsible for its phosphory-
lation. 
 
• VIG  shares  sequence  similarity  with  the  human  phos-
phoprotein Ki-1/57, a known substrate for protein kinase 
C (PKC). 
 
• VIG is efficiently phosphorylated by PKC in vitro, sug-
gesting PKC as a candidate kinase for VIG phosphoryla-
tion in vivo. 
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